Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
What you need to know about HIV two-drug regimens

Integrase inhibitors—potent antiretrovirals that quickly and powerfully suppress HIV—have allowed HIV researchers and clinicians to explore dosing regimens that involve fewer than three or four drugs. Proponents of dual therapy say that effective regimens involving fewer drugs will lower costs, decrease pill burden and reduce the potential for drug-drug interactions and side effects. But is it that simple?

Published
28 August 2018
From
BETA blog
Studies show dolutegravir monotherapy is an unsafe switch option

Using dolutegravir alone, as maintenance treatment after achieving undetectable viral load on a three-drug regimen, results in an unacceptable rate of viral rebound and is unethical in

Published
09 August 2018
By
Keith Alcorn
Reduced dose darunavir/ritonavir effective and safe for people switching while virally suppressed

A daily dose of the boosted protease inhibitor darunavir/ritonavir 400/100mg is at least as effective as therapy with lopinavir/ritonavir for people switching treatment while virally

Published
30 July 2018
By
Michael Carter
Dolutegravir durable with high rates of viral suppression in people who experienced virological failure with older integrase inhibitors

Antiretroviral regimens containing the integrase inhibitor dolutegravir are durable and achieve high rates of viral suppression in people who experienced virological failure with older integrase

Published
09 July 2018
By
Michael Carter
Rilpivirine better tolerated, less toxic and more durable than efavirenz in first-line ART

Rilpivirine is better tolerated, less toxic and more durable than efavirenz when used as part of a first-line antiretroviral regimen, investigators from Italy report in

Published
28 June 2018
By
Michael Carter
Meta-analysis of dolutegravir in naive, experienced and switch studies

A meta-analysis of 7340 participants in 13 randomised trials found efficacy and safety benefits for starting dolutegravir compared with other antiretrovirals in both naive and experienced participants. In the four switch studies in participants with undetectable viral load on their current ART, however, changing to dolutegravir was associated with more adverse events and discontinuations.

Published
30 April 2018
From
HIV i-Base
NHS England saved £10 million by switching to generic anti-HIV drugs in 2016

A programme to encourage clinicians to switch people to generic antiretroviral drugs saved the NHS almost £10 million in the financial year 2016-2017, Dr Laura

Published
30 April 2018
By
Roger Pebody
Switching from abacavir to TAF improves platelet function

People who switched from an antiretroviral regimen containing abacavir to one containing tenofovir alafenamide (TAF) showed less platelet reactivity, which reduces platelet aggregation or blood clotting, according to

Published
22 March 2018
By
Liz Highleyman
Failure of second-line ART is common in resource-limited countries, but modern third-line regimens work well

More than half of people in low- and middle-income countries may not maintain viral suppression on second-line antiretroviral therapy (ART), according to a study presented

Published
14 March 2018
By
Liz Highleyman
Biktarvy combo maintains viral suppression after switching therapy

People who switched to a single-tablet regimen containing the integrase inhibitor bictegravir were as likely to maintain an undetectable viral load as those who stayed on their

Published
07 March 2018
By
Liz Highleyman
← First12345...29Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.